Skip to main content
SpringerLink
Log in

Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Cutaneous adverse drug reactions are unpredictable and include various different skin conditions of varying degrees of severity. The most concerning are usually referred to as severe cutaneous adverse reactions (SCARs) and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DiHS) or hypersensitivity syndrome (HSS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). All are delayed type IV hypersensitivity reactions in which a T-cell-mediated drug-specific immune response is responsible for causing the disease. Nonetheless, specific T-cell subpopulations develop in response to certain environmental conditions and produce cytokines that orchestrate the various phenotypes. Cytotoxic T lymphocytes (CTLs), T-helper type 1 (Th1), Th2, Th17, and regulatory T cells (Treg), among other T-cell subpopulations, participate in the development of SCAR phenotypes. Cell subpopulations belonging to the innate immune system, comprising natural killer cells, innate lymphoid cells, monocytes, macrophages and dendritic cells, can also participate in shaping specific immune responses in various clinical conditions. Additionally, tissue-resident cells, including keratinocytes, can contribute to epidermal damage by secreting chemokines that attract pro-inflammatory immunocytes. The final phenotypes in each clinical entity result from the complex interactions between a variety of cell lineages, their products, soluble mediators and genetic and environmental factors. Although the pathophysiology of these reactions is not fully understood, intensive research in recent years has led to major progress in our understanding of the contribution of certain cell types and soluble mediators to the variability of SCAR phenotypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.

    Article  CAS  PubMed  Google Scholar 

  2. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977. p. 10–31.

    Google Scholar 

  3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–6.

    Article  CAS  PubMed  Google Scholar 

  4. Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625–45.

    PubMed  Google Scholar 

  5. Bellón T, Cabañas R, González-Herrada C, Ramírez E, González-Ramos J, López San Martín M, et al. Approach to severe cutaneous adverse drug reactions. Curr Treat Options Allergy. 2017;4(2):201–21.

    Article  Google Scholar 

  6. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Investig Dermatol. 2013;133(5):1197–204.

    Article  CAS  PubMed  Google Scholar 

  7. Bellón T, Blanca M. The innate immune system in delayed cutaneous allergic reactions to medications. Curr Opin Allergy Clin Immunol. 2011;11(4):292–8.

    Article  CAS  PubMed  Google Scholar 

  8. Bellon T. Effector cells and downstream mediators in severe cutaneous adverse reactions. Curr Immunol Rev. 2014;10(1):24–32.

    Article  CAS  Google Scholar 

  9. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JNB, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989–96.

    Article  CAS  PubMed  Google Scholar 

  10. Halevy S, Kardaun SH, Davidovici B, Wechsler J, EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010;163(6):1245–52.

    Article  CAS  PubMed  Google Scholar 

  11. De A, Das S, Sarda A, Pal D, Biswas P. Acute generalised exanthematous pustulosis: an update. Indian J Dermatol. 2018;63(1):22–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Investig. 2001;107(11):1433–41.

    Article  CAS  PubMed  Google Scholar 

  13. Padial MA, Alvarez-Ferreira J, Tapia B, Blanco R, Mañas C, Blanca M, et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol. 2004;150(1):139–42.

    Article  CAS  PubMed  Google Scholar 

  14. Roujeau JC, Haddad C, Paulmann M, Mockenhaupt M. Management of nonimmediate hypersensitivity reactions to drugs. Immunol Allergy Clin N Am. 2014;34(3):473–87.

    Article  Google Scholar 

  15. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1–17.

    Article  PubMed  Google Scholar 

  16. Saissi EH, Beau-Salinas F, Jonville-Béra AP, Lorette G, Autret-Leca E, Centres Régionaux de Pharmacovigilance. Drugs associated with acute generalized exanthematic pustulosis. Ann Dermatol Venereol. 2003;130(6–7):612–8.

    PubMed  Google Scholar 

  17. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–7.

    Article  CAS  PubMed  Google Scholar 

  18. Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol. 2013;168(2):391–401.

    Article  CAS  PubMed  Google Scholar 

  19. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006;155(2):301–6.

    Article  CAS  PubMed  Google Scholar 

  20. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Investig. 1988;82(6):1826–32.

    Article  CAS  PubMed  Google Scholar 

  21. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1(4):365–74.

    Article  CAS  PubMed  Google Scholar 

  22. Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol. 2007;33(1–2):124–33.

    Article  CAS  PubMed  Google Scholar 

  23. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–11.

    Article  CAS  PubMed  Google Scholar 

  24. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156(5):1083–4.

    Article  CAS  PubMed  Google Scholar 

  25. Ishida T, Kano Y, Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy. 2014;69(6):798–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.

    Article  CAS  PubMed  Google Scholar 

  27. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80.

    Article  CAS  PubMed  Google Scholar 

  28. Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac J-P, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2006;155(2):422–8.

    Article  CAS  PubMed  Google Scholar 

  29. Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017;16(2):139–47.

    CAS  PubMed  Google Scholar 

  30. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13(1):1–9.

    Article  PubMed  Google Scholar 

  31. Fernando SL. Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. Australas J Dermatol. 2014;55(1):15–23.

    Article  PubMed  Google Scholar 

  32. Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong T-A, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol. 2015;173(1):50–8.

    Article  CAS  PubMed  Google Scholar 

  33. Cho YT, Liau JY, Chang CY, Yang CW, Chen KL, Chen YC, et al. Co-existence of histopathological features is characteristic in drug reaction with eosinophilia and systemic symptoms and correlates with high grades of cutaneous abnormalities. J Eur Acad Dermatol Venereol. 2016;30(12):2077–84.

    Article  PubMed  Google Scholar 

  34. Shiohara T, Kano Y, Takahashi R, Ishida T, Mizukawa Y. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. In: French LE, editor. Adverse cutaneous drug eruptions. Basel: Karger; 2012. p. 122–38.

    Chapter  Google Scholar 

  35. George C, Sears A, Selim A-G, Walsh S, Creamer D. Systemic hypersensitivity reaction to Omnipaque radiocontrast medium: a case of mini-DRESS. Clin Case Rep. 2016;4(4):336–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ortonne N. Is DRESS syndrome a single entity or within a spectrum of adverse reactions to drug? Br J Dermatol. 2016;175(6):1142–4.

    Article  CAS  PubMed  Google Scholar 

  37. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2010;146(12):1373–9.

    Article  PubMed  Google Scholar 

  38. Cho Y-T, Chu C-Y. Treatments for severe cutaneous adverse reactions. J Immunol Res. 2017. https://doi.org/10.1155/2017/1503709.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Roujeau JC, Moritz S, Guillaume JC, Bombal C, Revuz J, Weil B, et al. Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis. Arch Dermatol Res. 1985;277(1):24–7.

    Article  CAS  PubMed  Google Scholar 

  40. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8 + lymphocyte involvement. Arch Dermatol. 1993;129(4):466–8.

    Article  CAS  PubMed  Google Scholar 

  41. Morel E, Escamochero S, Cabañas R, Díaz R, Fiandor A, Bellón T. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2010;125(3):703–10.

    Article  CAS  PubMed  Google Scholar 

  42. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.

    Article  CAS  PubMed  Google Scholar 

  43. Phillips EJ. New strategies to predict and prevent serious immunologically mediated adverse drug reactions. Trans Am Clin Climatol Assoc. 2018;129:74–87.

    PubMed  PubMed Central  Google Scholar 

  44. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119(1):225–30.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Yang Y, Li F, Du J, Shen Y, Lin J, Zhu X, et al. Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 2017;58(3):e61–7.

    Article  PubMed  Google Scholar 

  46. Heng YK, Lee HY, Roujeau J-C. Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol. 2015;173(5):1250–4.

    Article  CAS  PubMed  Google Scholar 

  47. Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38(1):75–86.

    Article  CAS  PubMed  Google Scholar 

  48. Dodiuk-Gad RP, Chung W-H, Valeyrie-Allanore L, Shear NH. Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475–93.

    Article  PubMed  Google Scholar 

  49. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60–8.

    Article  CAS  PubMed  Google Scholar 

  50. Olson D, Watkins LKF, Demirjian A, Lin X, Robinson CC, Pretty K, et al. Outbreak of Mycoplasma pneumoniae-associated Stevens–Johnson syndrome. Pediatrics. 2015;136(2):e386–94.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis. 1995;14(6):558–9.

    Article  CAS  PubMed  Google Scholar 

  52. Chung WH, Shih SR, Chang CF, Lin TY, Huang YC, Chang SC, et al. Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208(12):1968–78.

    Article  CAS  PubMed  Google Scholar 

  53. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis in United States adults. J Investig Dermatol. 2016;136(7):1387–97.

    Article  CAS  PubMed  Google Scholar 

  54. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens–Johnson syndrome in an HIV cohort. Am J Clin Dermatol. 2012;13(1):49–54.

    Article  PubMed  Google Scholar 

  55. Palmares J, Correia O, Delgado L, Vazsilva M, Mesquita-Guimaraes J, Castro-Correia J. Ocular involvement in toxic epidermal necrolysis. Ocul Immunol Inflamm. 1993;1(1–2):171–8.

    Article  CAS  PubMed  Google Scholar 

  56. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187–216.

    Article  CAS  PubMed  Google Scholar 

  57. Yang CW, Cho YT, Chen KL, Chen YC, Song HL, Chu CY. Long-term sequelae of Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta Dermato Venereol. 2016;96(4):525–9.

    Article  CAS  Google Scholar 

  58. Coombs R, Gell P. Classification of allergic reactions responsible for drug hypersensitivity reactions. In: Coombs RRA, Gells PGH, editors. Clinical aspects of immunology. Oxford: Blackwell Scientific Publications, Ltd; 1968. p. 575–96.

    Google Scholar 

  59. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–93.

    Article  CAS  PubMed  Google Scholar 

  60. Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007. p. 168–89.

    Chapter  Google Scholar 

  61. Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: key regulators of T-cell-mediated drug hypersensitivity. HLA. 2018;91(1):3–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Investig Dermatol. 2004;123(5):850–5.

    Article  CAS  PubMed  Google Scholar 

  63. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182(12):8071–9.

    Article  CAS  PubMed  Google Scholar 

  64. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol. 2002;2(4):325–31.

    Article  PubMed  Google Scholar 

  65. Schaerli P, Britschgi M, Keller M, Steiner UC, Steinmann LS, Moser B, et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol. 2004;173(3):2151–8.

    Article  CAS  PubMed  Google Scholar 

  66. Keller M, Spanou Z, Schaerli P, Britschgi M, Yawalkar N, Seitz M, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol. 2005;175(11):7678–86.

    Article  CAS  PubMed  Google Scholar 

  67. Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M, Tokura Y. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol. 2011;25(4):485–8.

    Article  CAS  PubMed  Google Scholar 

  68. Kakeda M, Schlapbach C, Danelon G, Tang MM, Cecchinato V, Yawalkar N, et al. Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res. 2014;306(10):933–8.

    Article  CAS  PubMed  Google Scholar 

  69. Teunissen MBM, Bos JD, Koomen CW, de Waal Malefyt R, Wierenga EA. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Investig Dermatol. 1998;111(4):645–9.

    Article  CAS  PubMed  Google Scholar 

  70. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol. 1999;162(1):494–502.

    CAS  PubMed  Google Scholar 

  71. Romagnani S, Maggi E, Liotta F, Cosmi L, Annunziato F. Properties and origin of human Th17 cells. Mol Immunol. 2009;47(1):3–7.

    Article  CAS  PubMed  Google Scholar 

  72. Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Investig Dermatol. 2013;133(7):1904–7.

    Article  CAS  PubMed  Google Scholar 

  73. Song HS, Kim SJ, Park T-I, Jang YH, Lee E-S. Immunohistochemical comparison of IL-36 and the IL-23/Th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis. Ann Dermatol. 2016;28(4):451–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, et al. Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis. J Investig Dermatol. 2018;139(4):848–58.

    Article  CAS  PubMed  Google Scholar 

  75. Mennicke M, Zawodniak A, Keller M, Wilkens L, Yawalkar N, Stickel F, et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant. 2009;9(9):2197–202.

    Article  CAS  PubMed  Google Scholar 

  76. Kitcharoensakkul M, Ree N, Bloomberg GR, Dehner LP, Heidingsfelder JA, White AJ, et al. Vancomycin-induced DRESS with evidence of T-cell activation in a 22-month-old patient. Ann Allergy Asthma Immunol. 2012;109(4):280–1.

    Article  PubMed  Google Scholar 

  77. An J, Lee JH, Lee H, Yu E, Lee DB, Shim JH, et al. Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report. Korean J Hepatol. 2012;18(1):84–8.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139(6):1026–32.

    Article  CAS  PubMed  Google Scholar 

  79. Ogawa K, Morito H, Hasegawa A, Daikoku N, Miyagawa F, Okazaki A, et al. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci. 2013;69(1):38–43.

    Article  CAS  PubMed  Google Scholar 

  80. Ange N, Alley S, Fernando SL, Coyle L, Yun J. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(3):1059–60.

    Article  PubMed  Google Scholar 

  81. Teraki Y, Fukuda T. Skin-homing IL-13-producing T cells expand in the circulation of patients with drug rash with eosinophilia and systemic symptoms. Dermatology. 2017;233(2–3):242–9.

    Article  CAS  PubMed  Google Scholar 

  82. Ogawa K, Morito H, Hasegawa A, Miyagawa F, Kobayashi N, Watanabe H, et al. Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS). Br J Dermatol. 2014;171(2):425–7.

    Article  CAS  PubMed  Google Scholar 

  83. Picard D, Janela B, Descamps V, D’Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2(46):46ra62.

    Article  CAS  PubMed  Google Scholar 

  84. Tsai YG, Liou JH, Hung SI, Chen CB, Chiu TM, Wang CW, et al. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptom. J Investig Dermatol. 2019;78:98. https://doi.org/10.1016/j.jid.2018.10.048.

    Article  CAS  Google Scholar 

  85. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134(4):710–4.

    Article  CAS  PubMed  Google Scholar 

  86. Nassif A, Bensussan A, Dorothée G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Investig Dermatol. 2002;118(4):728–33.

    Article  CAS  PubMed  Google Scholar 

  87. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–3.

    Article  CAS  PubMed  Google Scholar 

  88. Paquet P, Piérard GE. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med. 1998;1(2):459–62.

    CAS  PubMed  Google Scholar 

  89. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47(1):58–62.

    Article  PubMed  Google Scholar 

  90. Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, et al. Generalized bullous fixed drug eruption is distinct from Stevens–Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70(3):539–48.

    Article  CAS  PubMed  Google Scholar 

  91. Chang HY, Cooper ZA, Swetter SM, Marinkovich MP. Kinetics and specificity of Fas ligand induction in toxic epidermal necrolysis. Arch Dermatol. 2004;140(2):242–4.

    PubMed  Google Scholar 

  92. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens–Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162(5):1515–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. O’Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 2009;461(7264):659–63.

    Article  CAS  Google Scholar 

  94. Lotti R, Shu E, Petrachi T, Marconi A, Palazzo E, Quadri M, et al. Soluble Fas ligand is essential for blister formation in pemphigus. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.00370.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Hashizume H, Fujiyama T, Tokura Y. Reciprocal contribution of Th17 and regulatory T cells in severe drug allergy. J Dermatol Sci. 2016;81(2):131–4.

    Article  CAS  PubMed  Google Scholar 

  96. Teraki Y, Kawabe M, Izaki S. Possible role of TH17 cells in the pathogenesis of Stevens–Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2013;131(3):907–9.

    Article  CAS  PubMed  Google Scholar 

  97. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50.

    Article  CAS  PubMed  Google Scholar 

  98. Schlapbach C, Zawodniak A, Irla N, Adam J, Hunger RE, Yerly D, et al. NKp46 + cells express granulysin in multiple cutaneous adverse drug reactions. Allergy. 2011;66(11):1469–76.

    Article  CAS  PubMed  Google Scholar 

  99. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23(1):225–74.

    Article  CAS  PubMed  Google Scholar 

  100. Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, et al. Interleukin-15 is associated with severity and mortality in Stevens–Johnson syndrome/toxic epidermal necrolysis. J Investig Dermatol. 2017;137(5):1065–73.

    Article  CAS  PubMed  Google Scholar 

  101. Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau J-C, Kardaun S, et al. Evaluation of SCORTEN on a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32(2):237–45.

    Article  PubMed  Google Scholar 

  102. Castillo EF, Schluns KS. Regulating the immune system via IL-15 transpresentation. Cytokine. 2012;59(3):479–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Clayberger C, Krensky AM. Granulysin. Curr Opin Immunol. 2003;15(5):560–5.

    Article  CAS  PubMed  Google Scholar 

  104. Stern RS, Divito SJ. Stevens–Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology—thirty years of progress but still much to be done. J Investig Dermatol. 2017;137(5):1004–8.

    Article  CAS  PubMed  Google Scholar 

  105. Ueta M, Sawai H, Sotozono C, Hitomi Y, Kaniwa N, Kim MK, et al. IKZF1, a new susceptibility gene for cold medicine–related Stevens–Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135(6):1538–45.

    Article  CAS  PubMed  Google Scholar 

  106. Tapia B, Padial A, Sánchez-Sabaté E, Alvarez-Ferreira J, Morel E, Blanca M, et al. Involvement of CCL27-CCR106 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol. 2004;114(2):335–40.

    Article  CAS  PubMed  Google Scholar 

  107. Tohyama M, Watanabe H, Murakami S, Shirakata Y, Sayama K, Iijima M, et al. Possible involvement of CD14 + CD16 + monocyte lineage cells in the epidermal damage of Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2012;166(2):322–30.

    Article  CAS  PubMed  Google Scholar 

  108. de Araujo E, Dessirier V, Laprée G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN, et al. Death ligand TRAIL, secreted by CD1a + and CD14 + cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011;20(2):107–12.

    Article  CAS  PubMed  Google Scholar 

  109. Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Investig. 2018;128(3):985–96.

    Article  PubMed  Google Scholar 

  110. Bellón T, Alvarez L, Mayorga C, Morel E, Torres MJ, Martín-Díaz MA, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol. 2010;162(5):1014–22.

    Article  CAS  PubMed  Google Scholar 

  111. Paquet P, Nusgens BV, Piérard GE, Lapière CM. Gelatinases in drug-induced toxic epidermal necrolysis. Eur J Clin Investig. 1998;28(7):528–32.

    Article  CAS  Google Scholar 

  112. Gaultier F, Ejeil A-L, Igondjo-Tchen S, Dohan D, Dridi SM, Maman L, et al. Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens–Johnson syndrome. Arch Dermatol Res. 2004;296(5):220–5.

    Article  CAS  PubMed  Google Scholar 

  113. Arafat SN, Suelves AM, Spurr-Michaud S, Chodosh J, Foster CS, Dohlman CH, et al. Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with Stevens–Johnson syndrome and ocular cicatricial pemphigoid. Ophthalmology. 2014;121(1):79–87.

    Article  PubMed  Google Scholar 

  114. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010. https://doi.org/10.1155/2010/672395.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280(1):41–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Paquet P, Piérard GE. Epidermal calprotectin in drug-induced toxic epidermal necrolysis. J Cutan Pathol. 1999;26(6):301–5.

    Article  CAS  PubMed  Google Scholar 

  117. Paquet P, Piérard GE. Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med. 2002;10(2):145–7.

    PubMed  Google Scholar 

  118. Morel E, Alvarez L, Cabañas R, Fiandor A, Díaz R, Escamochero S, et al. Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions. Allergy. 2011;66(3):360–7.

    Article  CAS  PubMed  Google Scholar 

  119. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3(9):710–20.

    Article  CAS  PubMed  Google Scholar 

  120. Lehrer RI, Lu W. α-Defensins in human innate immunity. Immunol Rev. 2012;245(1):84–112.

    Article  CAS  PubMed  Google Scholar 

  121. Tewary P, Yang D, de la Rosa G, Li Y, Finn MW, Krensky AM, et al. Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin. Blood. 2010;116(18):3465–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Deng A, Chen S, Li Q, Lyu S-C, Clayberger C, Krensky AM. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol. 2005;174(9):5243–8.

    Article  CAS  PubMed  Google Scholar 

  123. Hashizume H, Fujiyama T, Kanebayashi J, Kito Y, Hata M, Yagi H. Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy. Allergy. 2013;68(5):681–9.

    Article  CAS  PubMed  Google Scholar 

  124. Fujita H, Matsukura S, Watanabe T, Komitsu N, Watanabe Y, Takahashi Y, et al. The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2014;171(6):1585–8.

    Article  CAS  PubMed  Google Scholar 

  125. Adachi A, Komine M, Tsuda H, Nakajima S, Kabashima K, Ohtsuki M. Differential expression of alarmins: IL-33 as a candidate marker for early diagnosis of toxic epidermal necrolysis. J Allergy Clin Immunol Pract. 2019;7(1):325–7.

    Article  PubMed  Google Scholar 

  126. Carr DF, Chung W-H, Jenkiins RE, Chaponda M, Nwikue G, Cornejo Castro EM, et al. 7th drug hypersensitivity meeting: part one. Clin Transl Allergy. 2016;6(S3):31.

    Article  CAS  PubMed Central  Google Scholar 

  127. Nakajima S, Watanabe H, Tohyama M, Sugita K, Iijima M, Hashimoto K, et al. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens–Johnson syndrome. Arch Dermatol. 2011;147(9):1110–2.

    Article  PubMed  Google Scholar 

  128. Carr DF, Wang C-W, Bellón T, Ressel L, Nwikue G, Shrivastava V, et al. Serum and blister-fluid elevation and decreased epidermal content of HMGB1 protein in drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.17610.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123(9):1171–3.

    Article  CAS  PubMed  Google Scholar 

  130. Pellicano R, Silvestris A, Iannantuono M, Ciavarella G, Lomuto M. Familial occurrence of fixed drug eruptions. Acta Derm Venereol. 1992;72(4):292–3.

    CAS  PubMed  Google Scholar 

  131. Melsom RD. Familial hypersensitivity to allopurinol with subsequent desensitization. Rheumatology (Oxford). 1999;38(12):1301.

    Article  CAS  PubMed  Google Scholar 

  132. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32.

    Article  CAS  PubMed  Google Scholar 

  133. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–2.

    Article  CAS  PubMed  Google Scholar 

  134. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. A marker for Stevens–Johnson syndrome. Nature. 2004;428(6982):486.

    Article  CAS  PubMed  Google Scholar 

  135. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134–9.

    Article  CAS  PubMed  Google Scholar 

  136. White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract. 2018;6(1):38–69.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araújo L, Correia O, et al. HLA and delayed drug-induced hypersensitivity. Int Arch Allergy Immunol. 2016;170(3):163–79.

    Article  CAS  PubMed  Google Scholar 

  138. Chen CB, Abe R, Pan RY, Wang CW, Hung SI, Tsai YG, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res. 2018. https://doi.org/10.1155/2018/6431694.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Phillips EJ. Defining regional differences in drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis: a tool to improve drug safety? Clin Pharmacol Ther. 2019;105(1):22–5.

    Article  PubMed  Google Scholar 

  140. Sousa-Pinto B, Pinto-Ramos J, Correia C, Gonçalves-Costa G, Gomes L, Gil-Mata S, et al. Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01. J Allergy Clin Immunol. 2015;136(4):1092–4.

    Article  CAS  PubMed  Google Scholar 

  141. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in europeans. N Engl J Med. 2011;364(12):1134–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Genin E, Chen D-P, Hung S-I, Sekula P, Schumacher M, Chang P-Y, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenom J. 2014;14(3):281–8.

    Article  CAS  Google Scholar 

  143. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom. 2006;16(4):297–306.

    Article  CAS  Google Scholar 

  144. Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168–78.

    Article  CAS  PubMed  Google Scholar 

  145. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genom. 2008;18(2):99–107.

    Article  CAS  Google Scholar 

  146. Shirzadi M, Thorstensen K, Helde G, Moen T, Brodtkorb E. Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study. Epilepsy Res. 2015;118:5–9.

    Article  CAS  PubMed  Google Scholar 

  147. Moon J, Park H-K, Chu K, Sunwoo J-S, Byun J-I, Lim J-A, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia. 2015;56(10):e161–7.

    Article  CAS  PubMed  Google Scholar 

  148. Zhang F-R, Liu H, Irwanto A, Fu X-A, Li Y, Yu G-Q, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–8.

    Article  CAS  PubMed  Google Scholar 

  149. Tangamornsuksan W, Lohitnavy M. Association between HLA-B*5901 and methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. Pharmacogenom J. 2018. https://doi.org/10.1038/s41397-018-0052-2.

    Article  Google Scholar 

  150. Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019. https://doi.org/10.1016/j.jaci.2019.01.045.

    Article  PubMed  Google Scholar 

  151. Jung J-W, Kim D-K, Park H-W, Oh K-H, Joo K-W, Kim Y-S, et al. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. Genet Med. 2015;17(10):807–14.

    Article  CAS  PubMed  Google Scholar 

  152. White KD, Chung WH, Hung SI, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response. J Allergy Clin Immunol. 2015;136(2):219–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Chen P, Lin J-J, Lu C-S, Ong C-T, Hsieh PF, Yang C-C, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33.

    Article  CAS  PubMed  Google Scholar 

  154. Venturi V, Price DA, Douek DC, Davenport MP. The molecular basis for public T-cell responses? Nat Rev Immunol. 2008;8(3):231–8.

    Article  CAS  PubMed  Google Scholar 

  155. Pichler WJ, Adam J, Watkins S, Wuillemin N, Yun J, Yerly D. Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immunol. 2015;168(1):13–24.

    Article  CAS  PubMed  Google Scholar 

  156. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554–8.

    Article  CAS  PubMed  Google Scholar 

  157. Norcross MA, Luo S, Lu L, Boyne MT, Gomarteli M, Rennels AD, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26(11):F21–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA. 2012;109(25):9959–64.

    Article  PubMed  Google Scholar 

  159. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol. 2013;25(1):81–9.

    Article  CAS  PubMed  Google Scholar 

  160. Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562–9.

    Article  CAS  PubMed  Google Scholar 

  161. Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens–Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266–76.

    Article  CAS  PubMed  Google Scholar 

  162. Lichtenfels M, Farrell J, Ogese MO, Bell CC, Eckle S, McCluskey J, et al. HLA restriction of carbamazepine-specific T-cell clones from an HLA-A*31:01-positive hypersensitive patient. Chem Res Toxicol. 2014;27(2):175–7.

    Article  CAS  PubMed  Google Scholar 

  163. Yun J, Mattsson J, Schnyder K, Fontana S, Largiadèr CR, Pichler WJ, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy. 2013;43(11):1246–55.

    Article  CAS  PubMed  Google Scholar 

  164. Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol. 2014;192(7):2984–93.

    Article  CAS  PubMed  Google Scholar 

  165. Chung WH, Pan RY, Chu MT, Chin SW, Huang YL, Wang WC, et al. Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions. J Investig Dermatol. 2015;135(9):2237–48.

    Article  CAS  PubMed  Google Scholar 

  166. Chen WT, Wang CW, Lu CW, Chen CB, Lee HE, Hung SI, et al. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Investig Dermatol. 2018;138(7):1546–54.

    Article  CAS  PubMed  Google Scholar 

  167. Zhao Q, Alhilali K, Alzahrani A, Almutairi M, Amjad J, Liu H, et al. Dapsone- and nitroso dapsone-specific activation of T-cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019. https://doi.org/10.1111/all.13769.

    Article  PubMed  Google Scholar 

  168. Illing PT, Mifsud NA, Purcell AW. Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. Curr Opin Immunol. 2016;42:31–40.

    Article  CAS  PubMed  Google Scholar 

  169. Rodriguez-Pena R, Lopez S, Mayorga C, Antunez C, Fernandez TD, Torres MJ, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to β-lactams. J Allergy Clin Immunol. 2006;118(4):949–56.

    Article  CAS  PubMed  Google Scholar 

  170. Lavergne SN, Wang H, Callan HE, Park BK, Naisbitt DJ. “Danger” conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther. 2009;331(2):372–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Gonçalo M, Martins J, Silva A, Neves B, Figueiredo A, Cruz T, et al. Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015;35(4):398–406.

    Article  CAS  PubMed  Google Scholar 

  172. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol. 2002;2(6):417–26.

    Article  CAS  PubMed  Google Scholar 

  173. Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe delayed drug reactions: role of genetics and viral infections. Immunol Allergy Clin N Am. 2017;37(4):785–815.

    Article  Google Scholar 

  174. Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract. 2014;2(1):21–33.

    Article  PubMed  PubMed Central  Google Scholar 

  175. Lucas A, Lucas M, Strhyn A, Keane NM, McKinnon E, Pavlos R, et al. Abacavir-reactive memory T cells are present in drug naïve individuals. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0117160.

    Article  PubMed  PubMed Central  Google Scholar 

  176. Adam J, Wuillemin N, Watkins S, Jamin H, Eriksson KK, Villiger P, et al. Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses. PLoS One. 2014. https://doi.org/10.1371/journal.pone.0095339.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Shiohara T, Ushigome Y, Kano Y, Takahashi R. Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):192–202.

    Article  CAS  PubMed  Google Scholar 

  178. Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol. 2015. https://doi.org/10.3389/fimmu.2015.00639.

    Article  PubMed  PubMed Central  Google Scholar 

  179. Chen X, Oppenheim JJ. Th17 cells and T regs: unlikely allies. J Leukoc Biol. 2014;95(5):723–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Ushigome Y, Mizukawa Y, Kimishima M, Yamazaki Y, Takahashi R, Kano Y, et al. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Clin Exp Allergy. 2018;48(11):1453–63.

    Article  CAS  PubMed  Google Scholar 

  181. Yang C, Mosam A, Mankahla A, Dlova N, Saavedra A. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4 + T cells. J Am Acad Dermatol. 2014;70(6):1096–102.

    Article  CAS  PubMed  Google Scholar 

  182. Cardone M, Garcia K, Tilahun ME, Boyd LF, Gebreyohannes S, Yano M, et al. A transgenic mouse model for HLA-B*57:01–linked abacavir drug tolerance and reactivity. J Clin Investig. 2018;128(7):2819–32.

    Article  PubMed  Google Scholar 

  183. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens–Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol. 1997;133(7):845–9.

    Article  CAS  PubMed  Google Scholar 

  184. Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, et al. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Investig Dermatol. 2013;133(2):489–98.

    Article  CAS  PubMed  Google Scholar 

  185. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209–15.

    Article  CAS  PubMed  Google Scholar 

  186. Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ. 2012;19(1):28–35.

    Article  CAS  PubMed  Google Scholar 

  187. Ichihara A, Wang Z, Jinnin M, Izuno Y, Shimozono N, Yamane K, et al. Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. J Allergy Clin Immunol. 2014;133(4):1065–74.

    Article  CAS  PubMed  Google Scholar 

  188. Saito N, Qiao H, Yanagi T, Shinkuma S, Nishimura K, Suto A, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med. 2014. https://doi.org/10.1126/scitranslmed.3008227.

    Article  PubMed  Google Scholar 

  189. Kearney CJ, Martin SJ. An inflammatory perspective on necroptosis. Mol Cell. 2017;65(6):965–73.

    Article  CAS  PubMed  Google Scholar 

  190. Kim SK, Kim W-J, Yoon J-H, Ji J-H, Morgan MJ, Cho H, et al. Upregulated RIP3 expression potentiates MLKL phosphorylation-mediated programmed necrosis in toxic epidermal necrolysis. J Investig Dermatol. 2015;135(8):2021–30.

    Article  CAS  PubMed  Google Scholar 

  191. Choi S-W, Park H-H, Kim S, Chung JM, Noh H-J, Kim SK, et al. PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent proteasomal degradation. Mol Cell. 2018;70(5):920–35.

    Article  PubMed  Google Scholar 

  192. Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol. 2019;80(3):670–8.

    Article  PubMed  Google Scholar 

  193. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328(23):1670–4.

    Article  CAS  PubMed  Google Scholar 

  194. Chung W-H, Chang W-C, Stocker SL, Juo C-G, Graham GG, Lee M-HH, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–64.

    Article  CAS  PubMed  Google Scholar 

  195. Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–34.

    Article  PubMed  Google Scholar 

  196. Ciccacci C, Di Fusco D, Marazzi MC, Zimba I, Erba F, Novelli G, et al. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013;69(11):1909–16.

    Article  CAS  PubMed  Google Scholar 

  197. Ciccacci C, Latini A, Politi C, Mancinelli S, Marazzi MC, Novelli G, et al. Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. Eur J Clin Pharmacol. 2017;73(10):1253–9.

    Article  CAS  PubMed  Google Scholar 

  198. Nicoletti P, Bansal M, Lefebvre C, Guarnieri P, Shen Y, Peer I, et al. ABC transporters and the proteasome complex are implicated in susceptibility to Stevens–Johnson syndrome and toxic epidermal necrolysis across multiple drugs. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0131038.

    Article  PubMed  PubMed Central  Google Scholar 

  199. Turner CT, Lim D, Granville DJ. Granzyme B in skin inflammation and disease. Matrix Biol. 2019. https://doi.org/10.1016/j.matbio.2017.12.005.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. La Paz Hospital Health Research Institute-IdiPAZ, Pº Castellana 261, 28046, Madrid, Spain

    Teresa Bellón

Authors
  1. Teresa Bellón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teresa Bellón.

Ethics declarations

Conflict of interest

Teresa Bellón has no conflicts of interest that are directly relevant to the content of this review.

Funding

This work was supported by Grant FIS PI13/01768 from Instituto de Salud Carlos III (co-founded by FEDER).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bellón, T. Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. Drug Saf 42, 973–992 (2019). https://doi.org/10.1007/s40264-019-00825-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-019-00825-2

Search

Navigation